Cover Image

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab

Saved in:

Bibliographic Details
Main Authors:	Marie Kubo (Author), Tomomitsu Miyagaki (Author), Hiroyuki Ohashi (Author), Arisa Kishi (Author), Kaoru Miyano (Author), Tatsuro Okano (Author), Mayuko Muto (Author), Sora Takeuchi (Author), Mitsuru Imamura (Author), Takafumi Kadono (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Poorly differentiated angiosarcoma with few vascular channels
by: Arisa Kishi, et al.
Published: (2020)

Decreased CXCL14 expression in psoriasis recovered by narrow‐band ultraviolet B therapy
by: Kaori Nakajima, et al.
Published: (2023)

Development of Nodular Lesions after Dupilumab Therapy in Erythrodermic Mycosis Fungoides with Interleukin-13 Receptor alpha2 Expression
by: Mina Hashimoto, et al.
Published: (2022)

Recurrent angiolymphoid hyperplasia with eosinophilia with CCR4 expression
by: Kaori Nakajima, et al.
Published: (2021)

Urticaria multiforme following nivolumab-ipilimumab therapy
by: Sonal Muzumdar, et al.
Published: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
by: Jason Zhang, et al.
Published: (2019)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
by: Kinjal Sanghavi, et al.
Published: (2020)

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
by: Yi Yang, et al.
Published: (2020)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
by: Yuri Sakaguchi, et al.
Published: (2020)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021)

Pediatric model‐based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma
by: Shengnan Du, et al.
Published: (2024)

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma
by: Andrey Moiseyenko, et al.
Published: (2020)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
by: John A. Storwick, et al.
Published: (2024)

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
by: Bushra Khan, et al.
Published: (2024)

Hyponatremia and Fever in a Patient on Ipilimumab and Nivolumab (Immune Checkpoint Inhibitors): A Case Report
by: Sumit S. Patel MD, et al.
Published: (2021)

Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review
by: Makoto Fujiwara, et al.
Published: (2023)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
by: Courtney M. Kenyon, BS, et al.
Published: (2024)

Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect
by: Zheyi Hu, et al.
Published: (2024)

Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid
by: Mika M. Tabata, BS, et al.
Published: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
by: Zhuo-miao Ye, et al.
Published: (2022)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
by: Matthew D. Tucker, et al.
Published: (2021)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
by: Bruno Sangro, et al.
Published: (2023)

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
by: Hang Xu, et al.
Published: (2019)

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
by: Alessandro Morabito
Published: (2024)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022)

Panhypopituitarism induced by ipilimumab
by: Miyu Shiratori, et al.
Published: (2020)

Ipilimumab: Melanoma and beyond
by: Vishal Patel, et al.
Published: (2011)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Severe lichenoid eruption due to concomitant medications following nivolumab administration
by: Risa Kakuta, et al.
Published: (2023)

Use of ipilimumab in the treatment of melanoma
by: Acharya UH, et al.
Published: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
by: Makiko Ban-Hoefen MD, et al.
Published: (2016)

Baker's Dozens
by: Harmon, Jim, 1933-2010

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
by: Akira Utsunomiya, et al.
Published: (2018)

Stage IV renal cell carcinoma achieves pathologic complete response after two ipilimumab plus nivolumab courses despite severe immune-related adverse events: a case report
by: Ryo Takada, et al.
Published: (2024)

Baker's Coconut Recipes
by: Franklin Baker Co

Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes
by: Chen P, et al.
Published: (2018)